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endocytosis and exocytosis of nanomedicines in human breast cancer cells.
Cancer nanomedicines are typically macromolecular drug delivery systems in the nanometer size range that 
are developed to reduce systemic toxicity but that also have the potential to exploit key features of solid tumor 
pathophysiology namely, leaky blood vessels and reduced lymphatic drainage to enhance passive tumor accumu-
lation1,2. Despite decades of research2,3, only a few anticancer nanomedicines are currently in routine clinical use; 
for example, Abraxane® (nanoparticle albumin-bound paclitaxel), Myocet® (liposomal doxorubicin), Doxil® 
(PEGylated liposomal doxorubicin), marketed as Caelyx® within Europe, Onivyde® (PEGylated liposomal irino-
tecan) and Daunoxome® (liposomal daunorubicin) are approved for treatment of solid tumors4. Speciically, 
Abraxane®5, Caelyx®6 and Myocet®7 are licensed for the treatment of advanced metastatic breast cancer no longer 
responsive to estrogen, progesterone and ERBB2 (Her2/neu) targeted therapies. he primary motivation for the 
development of these nanomedicine formulations has been the improvement in side efect proiles (e.g. reduc-
tion in doxorubicin-associated cardio toxicity) enabling the use of these cytotoxic drugs in heavily pre-treated 
patients6. However, the overall small number of this anticancer nanomedicine arsenal generally, relects the dif-
iculties encountered in the successful development of anticancer nanomedicines from concept through clinical 
practice8,9.
Many anticancer nanomedicine designs currently in preclinical and clinical development exploit the leaky 
vasculature and reduced lymphatic drainage of solid tumors as these tumor features favour the passive accumula-
tion of nanomedicines at the tumor sites. his phenomenon, irst described in 1986 and now commonly referred 
to as the “enhanced permeability and retention” (EPR) efect10. his arises due to a number of factors, including 
intratumoral hypoxia. Hypoxia in turn triggers angiogenesis and neo vascularisation principally via vascular 
endothelial growth factor11,12, platelet derived growth factor β and angiopoeitin-2 (ref.13). he result is dysregu-
lated and chaotic vascular growth, which commonly lacks stabilising smooth muscle cells. hese abnormal blood 
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vessels are heterogeneous but typically characterised by defective, irregular vascular endothelial cell coverage14. 
hese defective endothelial cells exhibit enlarged intercellular fenestrations, which facilitate the (passive) tumoro-
tropic transit and accumulation of nanomedicines (or macromolecules) within solid tumors (i.e. the EPR efect)15; 
acting against this trend is the raised internal tumor pressure16. Exploitation of the EPR efect in a clinical setting 
has proven di cult, and emerging evidence calls for better EPR-positive patient stratiication using image-guided 
approaches; this has now been pioneered in advanced metastatic breast cancer patients17.
Both tumor vascular development and density18, as well as perfusion and hypoxia, are key regulators of nano-
medicine distribution because nanomedicines are typically administered intravenously and must therefore suc-
cessfully complete their journey from the injection site to the tumor. Intratumoral hypoxia can be intermittent or 
transient19,20, which means that the physical access of a nanomedicine to hypoxic breast cancer tumor cells may 
be restricted to short, transient periods of vascular reperfusion. During reperfusion, the nanomedicine must nav-
igate physical barriers, such as the extracellular matrix and immune and cancer-associated cells (e.g., ibroblast, 
macrophages etc.), and must overcome physiological factors (e.g., high interstitial luid pressure) to reach the core 
of solid (breast) tumors21.
Hypoxia within the solid tumor itself is of particular importance. Typically, survival of tumor cells under 
hypoxic stress requires adaptation via a series of hypoxic induction factors (HIF), principally HIF122,23. hese 
factors consist of a constitutively expressed β subunit (ARNT; aryl hydrocarbon receptor nuclear translocator) 
and one of three oxygen-labile α subunits (denoted 1, 2 and 3). During periods of hypoxia, HIF1α, rather than 
undergoing normal proteasomal degradation24, translocates to the nucleus, where it combines with the HIFβ 
subunit to act on the conserved consensus sequence 5′-(A/G) CGTG-3′25, the hypoxic response element, in the 
promoter region of over 1,000 genes26,27. his triggers a cascade of cellular changes, with the overall result being 
clinically aggressive, highly metastatic28,29 and treatment resistant30,31 tumor growth.
However, of potentially greater signiicance from a nanomedicine perspective is that hypoxic adaptation also 
alters key cellular processes, including energy metabolism32–34, endocytic receptor internalisation35, transmem-
brane receptor recycling, traicking36 and signalling37. Nanomedicines designed for intracellular activation in 
cancer cells rely on endocytosis and correct intracellular traicking for efective therapeutic payload delivery. he 
energy dependence of endocytic uptake of nanomedicines means that these hypoxia-induced changes have the 
potential to directly undermine fundamental nanomedicine design principals. herefore, an inherent link exists 
between hypoxic status, re-oxygenation of hypoxic tumor cells and the cellular presentation and internalisation 
of nanomedicines. However, few if any studies have sought to rigorously quantify the impact of these biological 
changes upon nanomedicine uptake and retention. Given the dynamic nature of the hypoxic response and the 
myriad changes observed within hypoxic tumor cells, the aim of this study was to quantify, in vitro, the impact of 
hypoxia exposure, simulated reperfusion and dosing interval on nanomedicine internalisation and retention in 
triple negative, clinically aggressive human breast cancer cells. he MDA-MB-231 cell line was selected, because 
it is representative of the most diicult to treat breast cancer subtype (triple negative breast cancer)38, which is 
deicient in estrogen, progesterone and ERBB2 (Her2/neu) receptors39, MDA-MB-231 cells are therefore unre-
sponsive to hormone (e.g., Tamoxifen®) or receptor based therapies (e.g., Herceptin®) which are typical used to 
treat other breast cancer types. herefore to make progress with triple negative breast cancer there is the urgent 
need to better understand the performance of nanomedicines (e.g. nanoparticles) in the presence of hypoxia. his 
study quantiied the uptake and elux of nanoparticles in hypoxic conditioned MDA-MB-231 breast cancer cells 
and the bone metastatic subpopulation. In parallel, expression of key biological markers of the hypoxic cell stress 
response, including HIF1-α, was assessed.
Results
Monitoring the pericellular oxygen concentration. Mean pericellular oxygen was measured at each 
time point, for wells with media only or media plus MDA-MB-231 cells. Monitoring of pericellular oxygen levels, 
measured within cell culture wells, allowed an evaluation of the actual oxygen levels cultures were exposed to, as 
opposed to the regulated 1% oxygen environment in which they were conditioned. Following 30 minutes hypoxic 
exposure the mean percentage pericellular oxygen level for wells containing cells was lower than those with media 
only (2.3% versus 6.3% respectively) (Fig. 1, Supplementary Fig. S1). Pericellular oxygen levels reached 1.33%, 
following 1 hour incubation, ultimately declining to a mean pericellular oxygen level of 0.44% between the 10 and 
20 hour hypoxic conditioning period (Fig. 1). Exposure to atmospheric oxygen at 24 hours conditioning, resulted 
in transient elevation of pericellular oxygen levels, emulating the intermittent reperfusion seen with hypoxic 
tumors. Values returned to ≤ 1% within 50 minutes of resumption of hypoxic conditions.
ƪƥǤ he potential 
confounding efects from reduced cell viability due to nanoparticles (diameter 43.4 nm ± 4.4) were excluded by 
assessing cell viability irst. We selected this particle size because clinically used nanomedicines are typically 
within the 10 to 100 nm size range1,2. Furthermore, particles with a nominal diameter of 50 nm have no restric-
tions with respect to uptake routes into cells, which is encountered at larger particle sizes (e.g. >100 nm limited 
caveola uptake)2. Furthermore, polystyrene nanoparticles were selected to minimize any confounding efects (e.g. 
alternations of plasma membrane/endocytic membrane compositions)2. Cell viability over a 48 hour period was 
similar under either hypoxic or normoxic incubation conditions following exposure to the range of nanoparticle 
concentrations (Fig. 2a); no biological signiicant reduction of cell viability was observed (IC50 > 10
11 nanoparti-
cles/ml). Dual wavelength confocal imaging of live MDA-MB-231 cells revealed co-localisation of the luorescent 
nanoparticles with acidic intracellular vesicles, indicating endolysosomal uptake for both control and hypoxic 
cultures (Fig. 2b). he overall traicking pattern was similar for both normoxic and hypoxic cultures following a 
45 minutes and 180 minutes exposure to nanoparticles (Supplementary Fig. S2).
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Figure 1. Pericellular oxygen monitoring to emulate transient intratumoral reperfusion of breast tumor. 
Typical mean pericellular oxygen for cell culture wells with and without MDA-MB-231 cells. Pericellular oxygen 
monitoring over the entire experimental time course (for magniication see Supplementary Fig. S1). Data 
average n = 3 (for ± SD see Supplementary Fig. S1).
Figure 2. Cytotoxicity and uptake of nanoparticles in response to normoxia and hypoxia. (a) In vitro 
cytotoxicity of luorescent nanoparticles in the MDA-MB-231 human breast cancer cells. Cells were dosed 
with luorescent nanoparticles and subsequently cultured in either hypoxia (1% O2) or normoxia. At 48 hours 
cell viability was assessed. Dotted lines indicate the nanoparticle dose used for subsequent studies (n = 18 at 
each dosing point, from three biological replicates; ± SD). (b) Representative live cell confocal imaging of cells 
exposed for 24 hours to normoxia or hypoxia and subsequently dosed for 45 minutes with nanoparticles (green). 
Acidic vesicles were stained using LysoTracker Red. Arrows show nanoparticle co-localisation in acidic vesicles. 
Scale bar 20 µm.
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ǦǦ ? ? ?Ǥ The phenotypic adaptation of 
MDA-MB-231 cells exposed to hypoxia was monitored by assessing the expression of 11 cell stress related pro-
teins, including HIF1α, the key efector of hypoxic adaptation, ater 0, 6 and 24 hours of hypoxic conditioning 
(Fig. 3). he protein array results from cell lysates demonstrated diferentially regulated cell stress associated 
proteins. For example, HIF1α levels were highest ater 6 hours of hypoxia but remained slightly elevated ater 
24 hours of hypoxia when compared to normoxic cultures. Carbonic anhydrase 9 expression showed a close to 
2 fold increase from 6 hours to 24 hours (relative measured luorescence 21,003 and 39,116, respectively). CbP/
p300 – interacting transactivator -2 (Cited-2) exhibited a similar expression proile, with elevated levels following 
6 hours hypoxia, whereas hioredoxin-1 increased progressively across the 24 hours hypoxic period (Fig. 3).
HIF1α is a master regulator of the hypoxic response; therefore, the protein array results were veriied by SDS 
PAGE and western blotting to determine the relative HIF1α expression in biological replicates (Supplementary 
Fig. S3a). he immunoblotting results conirmed the HIF1α expression pattern observed with the protein array 
(Fig. 3, Supplementary Fig. S3b); namely, the HIF1α expression levels were highest ater 6 hours of hypoxic incu-
bation (a 4.10-fold increase) and lower at 24 hours (a 1.54-fold increase), whereas the control cultures showed no 
substantial change in HIF1α (1.0-fold).
Ǥ he relative 
expression of cell stress related proteins, and in particular, the diferential expression of HIF1α observed ater 
6 or 24 hours of hypoxic conditioning led to the choice of these time points for uptake studies in MDA-MB-231 
human breast cancer cells (Fig. 4a). Following the respective hypoxia conditioning, MDA-MB-231 cells were 
exposed to nanoparticles for either 45 or 180 minutes. When compared to the respective normoxic controls, 
nanoparticle uptake at 45 minutes was signiicantly increased in cells exposed to 6 hours of hypoxic conditioning. 
With the same hypoxic conditioning regime nanoparticle uptake was substantially upregulated at 180 minutes 
(Fig. 4). By contrast, cells conditioned for 24 hours under hypoxia showed signiicantly increased nanoparticle 
uptake at both the 45 and 180 minute dosing intervals when compared to normoxic control cultures. he largest 
overall upregulation of nanoparticle uptake (10.02% ± 5.36) was observed at the 45 minute dosing interval in cells 
conditioned under hypoxia for 24 hours (Fig. 4b). hese observations were veriied with the 1833 breast cancer 
subline (originally derived from MDA-MB-231 via in vivo selection40). 1833 cells were conditioned for 24 hours 
in hypoxia and dosed with nanoparticles for 45 minutes also resulting in an increased (7.96% ± 4.35) nanoparticle 
uptake (Fig. 5a,b).
he observation that hypoxic conditioned MDA-MB-231 and 1833 cells showed consistently increased nan-
oparticle uptake raised the possibility that this response was due to (i) increased endocytosis (i.e. uptake), (ii) 
reduced exocytosis (i.e. recycling) or (iii) a combination of both (i) and (ii). his question was addressed by 
performing pulse chase experiments with normoxic and hypoxic conditioned cells. hese studies were conducted 
with MDA-MB-231 and 1833 cells conditioned for 24 hours to hypoxia and pulse dosed for 45 minutes, as this 
treatment gave the greatest relative increase in nanoparticle uptake (Figs 4c and 5c). Ater this treatment, the 
cells were chased for 30 minutes and then analysed. Comparison of the baseline cell-associated luorescence 
with post chase cell-associated luorescence demonstrated a post-chase drop in the MDA-MB-231 cells which 
was signiicantly greater following hypoxic conditioning than following normoxic conditioning (81.13% ± 2.18, 
Figure 3. Impact of hypoxia on cell stress related proteins in human MDA-MB-231 breast cancer cells. Cells 
were conditioned in hypoxia (1% O2) for either 0, 6 or 24 hours. Relative expression of cell stress related proteins 
in whole cell lysates using antibody protein arrays (pooled lysates from 3 samples). Full names: CAIX, carbonic 
anhydrase 9; Cited-2, CbP/p300 – interacting transactivator – 2; HIF1α, α subunit of hypoxic induction factor 
1; HIF2α, α subunit of hypoxic induction factor 2; HSP60, heat shock protein 60; HSP70, heat shock protein 70; 
Phospho p53 (s46), phosphorylated p53; SIRT2, NAD-dependent deacetylase sirtuin-2; SOD2, mitochondrial 
superoxide dismutase 2.
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n = 15 and 72.14% ± 4.94, n = 15, respectively) (Fig. 4). Similarly the post-chase drop in the 1833 cells was also 
signiicantly greater following hypoxic conditioning than with normoxic conditioning (52.09% ± 4.75, n = 10 and 
43.74% ± 10.13, n = 10, respectively) (Fig. 5c).
Discussion
We believe this is the irst quantitative study on human breast cancer cells that assesses the impact of hypoxic 
adaptation on both nanomedicine internalisation and recycling whilst also taking into account the temporal 
changes in key elements of the hypoxic adaptation circuit itself. Recent mechanistic insights into nanomedicine 
access to tumor cells includes transient vascular bursts41,42 and a combination of radiotherapy and tumor associ-
ated macrophages (TAM) that show the potential to enhance therapeutic delivery of nanomedicines via the char-
acteristically short periodic vascular reperfusion43 found in tumors. In experimental xenograts these vascular 
burst were dependent on blood low, were intermittent and facilitated nanomedicine distribution into large areas 
of the tumor (100s µ2) (ref.42). We therefore designed our uptake studies so that nanomedicine dosing occurred at 
the start of short periods of re-oxygenation, followed by hypoxia, to relect the current understanding of transient 
tumor vascular reperfusion44, and the subsequent access of nanomedicines to the intratumoral space.
his study examined the impact of hypoxia on nanoparticle endo- and exocytosis using a simple, but yet 
efective and well-controlled two-dimensional in vitro culture system. he merit of our system is the ability to 
both monitor pericellular oxygen levels non-invasively and to quantify nanoparticle uptake and elux. Unlike 
three-dimensional organotypic culture models our model system reduced the complexity thus eliminating 
co-founding factors such as mass transport limitations (of both nanoparticles and oxygen) and permitting rapid 
sample processing and analysis. Rapid sample handling is important to ensure that endocytosis and exocytosis is 
arrested (here by placing samples on ice). While this study demonstrates the basic role of hypoxia in nanoparticle 
uptake and elux, many other factors are likely to impact nanomedicine performance. A number of normoxic 
studies have considered factors like stability of the carrier, cargo release and particle size and elasticity45. However, 
this study was deigned speciically to exclude as many of these confounding factors as possible.
Our data showed that nanomedicine internalisation is altered in a dynamic fashion in response to varying 
periods of hypoxic conditioning and dosing intervals. hese indings paralleled the altered expression of key 
proteins within the hypoxic adaptation circuit itself. MDA-MB-231 cells increased their capacity for internalisa-
tion of nanoparticles in response to hypoxic conditioning for 6 or 24 hours, with the greatest diference observed 
Figure 4. Impact of hypoxic preconditioning on the uptake (endocytosis) and recycling (exocytosis) of 
nanoparticles by human MDA-MB-231 breast cancer cells. (a) Diagram of the experimental approach. Cells 
were conditioned in hypoxia (1% O2) for either 6 or 24 hours and then dosed with nanoparticles at an efective 
concentration of 1 × 1010 nanoparticles/ml for either 45 or 180 minutes. For the recycling studies, cells were 
preconditioned for 24 hours in either hypoxia (1% O2) or normoxia. Next, cells were dosed with nanoparticles 
at an efective concentration of 1 × 1010 nanoparticles/ml for 45 minutes and analysed (baseline), or washed 
and allowed to exocytose for 30 minutes (exocytosis) (b) Cell uptake of luorescent nanoparticles was assessed 
by measuring mean single cell-associated luorescence by low cytometry. (c) Exocytosis of luorescent 
nanoparticles of normoxia or hypoxia preconditioned cells. For (b,c) mean single cell-associated luorescence 
was measured by low cytometry; ≥10,000 events; n = 15 for each dosing group and treatment period, 3 
independent biological experiments ± SD.
www.nature.com/scientificreports/
6SCIENTIFIC REPORTS |  (2018) 8:12318 ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
following 24 hours hypoxia. In addition, following all hypoxic conditioning periods, the greatest relative increase 
in internalisation was observed over a 45 minute dosing interval. he MDA-MB-231 parent cell line is heteroge-
neous and contains adapted, highly metastatic sub-populations40,46. We therefore examined the performance of 
nanoparticles in the bone metastatic subline 1833 because bone metastasis is common in triple negative breast 
cancer47. We examined the cellular response in MDA-MB-231 and 1833 cells (classiied as mesenchymal-like) 
to make inroads into the efects of tumor heterogeneity (within the same patient) on nanomedicine uptake and 
elux in hypoxia. However, gene expression analysis of triple negative breast cancer has identiied six main sub-
types (mesenchymal-like cells are one of them)48. It thus remains to be seen how all these diferent subclasses of 
triple negative cells respond to hypoxia.
Similarly to the parent cell line, 24 hour hypoxic conditioning of 1833 cells followed by a 45 minute dosing 
interval showed a signiicant increase in nanoparticle uptake. Furthermore, both the MDA-MB-231 and 1833 
cell lines conditioned to hypoxia for 24 hours increased their exocytosis of nanoparticles. We therefore speculate 
that hypoxic endocytic uptake and recycling are similar in both these mesenchymal-like breast cancer cell lines. 
However, systematic studies examining these diferences have not been reported. Overall, these results demon-
strate that intratumoral hypoxia has the potential to alter nanomedicine uptake by tumor cells, thereby modifying 
intracellular traicking and confounding efective therapeutic payload delivery.
A key aspect of the hypoxic response is the shit from energy-eicient oxidative phosphorylation to the less 
productive, yet oxygen conserving, glycolytic pathway49–51. As a consequence, hypoxic tumor cells enter a lower 
energy state associated with reduced ATP synthesis. Because nanomedicine internalisation via endocytosis is 
an active, energy-dependent process, the expectation would be a reduction in nanomedicine internalisation, 
yet here, we observed a signiicant increase. here are however, few studies available for comparison with our 
work. One study reported a reduction in the cellular uptake of 1.9 nm gold nanoparticles in MDA-MB-231 cells 
under hypoxic conditions52. However, that study employed a very low (0.1%) oxygen environment for hypoxic 
conditioning and the conditioning was only for 4 hours prior to dosing with nanoparticles. Some cellular hypoxic 
adaptations would be expected over that short duration of hypoxia, but no validations of molecular changes 
were reported and pericellular oxygen levels were not determined. In the present study, therefore, we adopted in 
situ pericellular oxygen monitoring and tracked 11 stress related proteins (including the master hypoxic efec-
tor, HIF1α) as markers of hypoxic cellular conditioning and the cellular hypoxic response, respectively. By con-
trast, Neshatian et al.53 demonstrated elevated internalisation of gold nanoparticles (sizes: 15, 50 and 70 nm) in 
human MCF-7 breast cancer cells following 18 hours of hypoxic pre-conditioning in a very low 0.2% oxygen 
Figure 5. Impact of hypoxic preconditioning on the uptake (endocytosis) and recycling (exocytosis) of 
nanoparticles by human 1833 breast cancer cells. (a) Diagram of the experimental approach. Cells were 
conditioned in hypoxia (1% O2) for 24 hours and then dosed with nanoparticles at a concentration of 1 × 10
11 
nanoparticles/ml for 45 minutes. For the recycling studies, cells were preconditioned for 24 hours in either 
hypoxia (1% O2) or normoxia. Next, cells were similarly dosed for 45 minutes and analysed (baseline) or 
washed and allowed to exocytose for 30 minutes (exocytosis) (b) Cell uptake of luorescent nanoparticles was 
assessed by measuring mean single cell-associated luorescence by low cytometry. (c) Exocytosis of luorescent 
nanoparticles of normoxia or hypoxia preconditioned cells. Mean single cell-associated luorescence was 
measured by low cytometry, ≥10,000 events per measurement; (b) n = 15 from 3 independent biological 
experiments, (c) n = 20 for each treatment period, 2 independent biological experiments ± SD.
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environment. For our study, we selected a hypoxic oxygen level of 1% because meta-analysis54 of in vivo ultra-
sound guided hypoxia measurements within human breast tumors indicated that the median pO2 was 10 mmHg. 
Using normobaric assumptions, this approximates to around 1.0 to 1.3% oxygen. As expected, we found lower 
pericellular oxygen in the presence of cells than in cell-free media (Fig. 1). his suggests that an incubation envi-
ronment as low as 0.2 or 0.1% O2, as used in the previous published studies, could lead to anoxic, as opposed to 
hypoxic, conditions within the cells themselves55. his is important, because anoxia is known to trigger alternative 
cellular responses (e.g. activating transcription factor 3 and 4) that are not mediated via HIF56,57. his raises con-
cerns about the relevance of these previously published studies in the context of nanomedicines and limits our 
ability to compare our work with them.
Overall, nanomedicine retention within cells is the sum of both uptake (i.e. endocytosis) and elux (i.e. exo-
cytosis)3 and requires a mechanism for regulation of cellular homeostasis (e.g. cell volume, plasma membrane 
economics)58 and for response to and modulation of cell signalling (e.g. receptor recycling versus down reg-
ulation). herefore, assessment of the endocytic index of nanomedicines must include both endocytosis and 
exocytosis3. he current results showed that 24 hour hypoxic preconditioning increased nanomedicine uptake, 
but it also increased exocytosis (Figs 4 and 5). he degree and speed of recycling under normoxic conditions we 
have observed here is similar to that noted in previous work (albeit, under difering experimental conditions)59,60.
he observed upregulation of the energy dependent processes of endo- and exocytosis, in what is ostensibly 
a low energy hypoxic cellular state, would appear to be counterintuitive. However, tumor cell hypoxic adaptation 
involves well-established changes to endocytic receptor uptake and signalling35,61,62 and altered intracellular traf-
icking36. Recent in vitro research has shown that MDA-MB-231 and HeLa cells undergo a generalised reduction 
in overall internalisation of the tumor cell surface proteome in response to hypoxia, with a parallel selective 
upregulation of speciic endocytic pathways, mediated via caveolin 1 (ref.63). Further, the recycling of transmem-
brane proteins may also be inluenced by interaction with proteins like Caveolin 1, among others64. Interestingly, 
constitutive in vitro expression of Caveolin 1 is markedly higher in MDA-MB-231 cells than in many other tumor 
cell lines65,66, suggesting its potential for a greater inluence in this cell line. Similarly, upregulation of exocytotic 
release of exosomes or vesicles from tumor cells during hypoxia is known to play a signiicant role in tumor devel-
opment and signaling37,67, with implications for altered or upregulated exocytosis. hus, our results may relect 
these types of speciic upregulated endocytic and exocytic processes, which deserve further investigation.
Our study measured relative expression of HIF1α, the master efector of hypoxic adaptation, to assess how 
the cellular hypoxic response might change with the duration of hypoxic exposure. Unhydroxylated HIF1α 
expression was increased approximately four fold when compared to normoxic levels ater 6 hours of hypoxia, but 
returned to near normoxic levels following 24 hours of hypoxia. Similar temporal patterns of HIF1α expression 
have been demonstrated in MDA-MB-231 cells exposed to similar in vitro hypoxic conditions68. he regulation 
of this cyclical HIF1α expression is multifactorial, but it appears to be driven principally by a variety of cellular 
factors, including REST (repressor element 1- silencing transcription factor)68. In the context of our results, it is 
interesting to note that we observed the greatest diferences in nanoparticle internalisation following 24 hours of 
hypoxic conditioning, where we also found that HIF1α had returned to near normal levels.
We assessed the relative expression of ten other key cell stress proteins in the MDA-MB-231 cells and demon-
strated that their altered expression depended on the duration of hypoxia. Whilst all these proteins are relevant 
to the cellular stress response to hypoxia, of particular note are those known to form part of the HIF1 regulatory 
circuit. For example, CbP/p300 – interacting transactivator – 2 (Cited 2) is a known HIF1 negative regulatory 
element that exhibits preferential binding of CBP/p300 co-factors required for HIF1 transcriptional activity69. 
Similarly, the NAD dependent deacetylase Sirtuin2 (SIRT2) has been shown, through deacetylation, to increase 
proteasomal breakdown of HIF1 via enhanced ainity for PHD270. We found that the relative expression of Cited 
2 peaked following six hours of hypoxia, whereas Sirtuin2 exhibited the highest relative expression following 
24 hours of hypoxic conditioning. Taken within the context of our studies, these results underline the dynamic 
nature of hypoxic adaptation within tumor cells and its impact on the uptake and elux of nanomedicines during 
hypoxia.
Conclusions
he objective of this work was to quantify the diference that tumor cell hypoxic adaptation might make to in 
vitro nanomedicine uptake and recycling (Fig. 6). We demonstrated that both uptake and recycling of our model 
nanomedicine were increased following hypoxic incubation in both the MDA-MB-231 and 1833 cell line. Further, 
we demonstrated with the MDA-MB-231 cell line, that the magnitude of these changes depended on the duration 
of the hypoxic exposure and the dosing interval. Overall, these results expand the existing knowledge of how 
the hypoxic tumor microenvironment can potentially alter nanomedicine internalisation, with implications for 
efective therapeutic delivery and design.

Cell culture. MDA-MB-231 cells (ATCC® HTB-26™) were purchased from the American Type Culture 
Collection (Manassas, VA, USA). he 1833 subline was gited by Dr. Joan Massagué (Memorial Sloan-Kettering 
Cancer Center, New York, NY, USA) and detailed elsewhere40. Cells were cultured as monolayers in RPMI 1640 
media (Life Technologies, UK), supplemented with 10% (v/v) foetal bovine serum (FBS), 50 U/mL penicillin and 
50 µg/mL streptomycin. Unless otherwise indicated, cells were seeded at 4 × 104 cells/cm2. For all experimental 
work, hypoxic or normoxic culture conditions were achieved using a gas mixture of 5% CO2, 1% O2 and 87.8% 
N2 (hypoxic) or 5% CO2, 18.6% O2 and 70.2% N2 (normoxic) within a humid 37°C incubator. Normobaric con-
ditions were assumed throughout.
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Fluorescent nanoparticles. Fluoresbrite® spherical fluorescent polystyrene nanoparticles (diameter 
43.4 nm ± 4.4 with an excitation/emission maxima at 441/486 nm), suspended in water, were purchased from 
Polysciences Europe GmbH, Eppelheim, Germany.
In vitro cytotoxicity studies. MDA-MB-231 cells were seeded into 96-well tissue culture treated polysty-
rene plates (TPP Techno Plastic Products AG, Trasadingen, Switzerland) at a density of 3 × 103 cells/cm2 in 100 µl 
complete culture medium. he plates were then incubated in either normoxic or hypoxic conditions for 24 hours. 
he wells were then aspirated and fresh media containing nanoparticles at a range of concentrations up to 1 × 1011 
nanoparticles/ml was added, followed by a further incubation in the respective environment for 44 hours. Next, 
20 µl of (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg/ml in PBS) was added and 
incubated for 4 hours. he MTT was aspirated from all wells and formazan crystals were dissolved in dimethyl 
sulphoxide and absorbance read at 570 nm. Cell viability at each nanoparticle dose was calculated as a percentage 
of the control (i.e. zero dose).
In vitroƥƪǤ MDA-MB-231 cells were seeded onto cell culture 
treated polystyrene Cellstar® cell culture dishes (Greiner Bio-One, Kremsmunster, Austria) for 24 hours in either 
hypoxic or normoxic conditions (as deined above). Next, cells were dosed with luorescent nanoparticles for 
either 45 or 180 minutes, placed on ice and washed twice with PBS at 4 °C, stored on ice and transferred for confo-
cal imaging immediately. Lysosomal staining was achieved using LysoTracker® Red (Invitrogen, Waltham, MA, 
USA) according to the manufacturer’s instructions. Live cell confocal co-localisation imaging was conducted 
using a Leica TCS SP5 laser scanning confocal microscope equipped with a 40× liquid immersion objective. 
Confocal slices were assembled into igures, brightness/contrast adjusted using ImageJ v1.0 (National Institutes 
of Health, Bethesda, Maryland, USA) and imported into Graphpad Prism® v7.0 (GraphPad Sotware Inc., La 
Jolla, CA, USA).
Generation of cell lysates. MDA-MB-231 cells were seeded in 75 cm2 tissue culture treated polystyrene 
culture lasks and incubated for 24 hours under normoxic conditions to support cell growth. Next, lasks were split 
into 4 groups and cultured for a further 24 hours using speciic conditioning regimes: (i) normoxic control, (ii) 
6 hours of hypoxia (i.e. 18 hours normoxia followed by 6 hours of hypoxia conditioning), (iii) 24 hours of hypoxic 
conditioning and (iv) positive control using 100 µM CoCl2. The CoCl2 dosing served to chemically block 
HIF1α breakdown in the presence of oxygen. At the end of the conditioning regime, samples were immediately 
immersed in ice. Within 90 seconds, the culture medium was removed and the cell monolayers were washed twice 
with 5 ml ice cold PBS, followed by 1.0 ml of ice cold radioimmunoprecipitation (RIPA) bufer containing 40 µl 
of 25 × Roche Diagnostics Easypack® Protease cocktail (both from Sigma-Aldrich, Dorset, England, UK). he 
cells were then harvested using a cell scraper. he lysates were pipetted into ice cold centrifuge tubes and, while 
maintained at 4 °C, vortexed at full power for 1 minute, shaken at full power for 20 minutes and then centrifuged 
for 20 minutes at 12,000 × g. Following centrifugation, the supernatant was aliquoted and stored at −80°C until 
further analysis.
ǡǤ he total protein concentration of each cell 
lysate was determined using the Pierce™ bicinchoninic acid protein assay kit (hermo Scientiic, Waltham, MA, 
USA). Protein samples were denatured in a 1:1 ratio using Laemmli sample loading bufer [65.8 mM Tris-HCl, pH 
6.8, 2.1% (w/v) SDS, 26.3% (w/v) glycerol, 0.01% (v/v) bromophenol blue, and 5% (v/v) 14.2 M β-mercaptoethanol 
Figure 6. A schematic summary of key indings: Hypoxic conditioning of breast cancer cells increases 
nanomedicine uptake and elux.
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(Bio-Rad Laboratories, Hemel Hempstead, UK)] by heating for 5 minutes at 95 °C. Equivalent protein quantities 
(25 µg) and a Precision Plus Kaleidoscope™ protein ladder (Bio-Rad Laboratories, Hemel Hempstead, UK) were 
loaded on to an 8% polyacrylamide gel, and separated at 150 V for 55 minutes. Proteins were blotted onto a 
polyvinylidene diluoride membrane (Bio-Rad Laboratories, Hemel Hempstead, UK). he following antibodies 
were used to probe the membrane: Rabbit primary antibodies for β-actin (1:10,000) and unhydroxylated HIF1-α 
(1:1,000) (monoclonal and polyclonal respectively) as well as monoclonal goat anti-rabbit IgG HRP linked sec-
ondary antibody (1:2,000) (all from Cell Signalling Technology, Danvers, MA, USA). Primary antibodies were 
blocked with 5%w/v bovine serum albumin (Sigma-Aldrich, Dorset, England, UK) in tris-bufered saline Tween 
(TBST), with secondary antibody blocking achieved with 5% non-fat dry milk powder in TBST. Relevant bands 
were visualised using Clarity™western ECL substrate and UltraCruz autoradiography ilm (Santa Cruz Biotech 
Inc., Dallas, TX, USA). HIF1-α and β-actin bands were digitised (Epson Perfection v600 ilm latbed scanner, 
Epson Europe, B.V., Netherlands), and densitometry scans were completed using Image Studio™ Lite sotware 
(LI-COR Biotechnology, Lincoln, NE, USA). he relative expression of 11 cell stress-associated proteins was 
determined using the R&D Proteome proiler™ (catalogue number #ARY018; R&D Systems, Inc., MN, USA), fol-
lowing the manufacturer’s instructions. Triplicates of cell lysates were prepared as detailed above and pooled, with 
a total of 300 µg protein per sample used. Arrays were imaged and analysed by densitometry, as detailed above.
Ǥ MDA-MB-231 or 1833 
cells were seeded into 6-well plates. Plates were then incubated for either (i) 24 hours in hypoxic conditions, (ii) 
24 hours in normoxic conditions, or (iii) 18 hours under normoxia followed by 6 hours under hypoxia. Cells were 
then dosed with nanoparticles at an efective concentration of 1 × 1010 nanoparticles/ml (1 × 1011 nanoparticles/
ml for 1833 cells), and the plates were returned to their respective culture environments for either 45 or 180 min-
utes. For the recycling studies, cells were preconditioned for 24 hours in either hypoxia (1% O2) or normoxia. 
Next, cells were dosed with nanoparticles at an efective concentration of 1 × 1010 nanoparticles/ml (1 × 1011 
nanoparticles/ml for 1833 cells) for 45 minutes and analysed (baseline), or washed and allowed to exocytose for 
30 minutes (exocytosis). Within the next 15 minute time interval, the cells were washed 3 times with ice cold PBS, 
detached using trypsin and transferred to low cytometry tubes for analysis. Flow cytometry was performed using 
a FACS Canto™II FACS analyser (Becton Dickinson, Oxford, England, UK) by assessing mean cell-associated 
luorescence with an argon laser (excitation 488 nm, emission 525 nm) and gating 10,000 events. For all hypoxic 
measurements normoxic control groups were run in parallel. Mean FITC luorescence values were determined 
from FCS 3.0 iles using FlowJo® v10.3 sotware (FlowJo LLC, Oregon, USA). Mean FITC luorescence values 
(Supplementary Fig. S4) were converted into percentages to calculate relative diferences.
Pericellular oxygen monitoring. hree wells of Presens Oxohydrodish® 6 well plates (Presens, Precision 
Sensing GmbH, Regensburg, Germany) were seeded with MDA-MB-231 cells, as described above. he remain-
ing three wells were illed with an equivalent volume of medium only. Each plate was then placed on the Presens 
Sensordish® 24-channel plate reader within the hypoxic incubator. Following temperature equilibration, the 
in-well oxygen percentage was recorded for each well, separately, at frequent intervals, for a period of up to 
26 hours.
Statistical analyses. Statistical analyses were performed using GraphPad Prism® v6.0 (Graphpad Sotware 
Inc., La Jolla, CA, USA). All signiicance tests used unpaired two tailed Student’s t tests, except for cytotoxicity 
measurements, where a one-way unpaired ANOVA with Sidak multiple comparisons test was used (α = 0.05). 
Asterisks denote statistical signiicance as follows: *p < 0.05, **p < 0.01 and ***p < 0.001. All data are presented 
as a mean values ± standard deviation (SD), unless otherwise stated.
References
 1. Shi, J., Kantof, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 
17, 20–37 (2016).
 2. Duncan, R. & Gaspar, R. Nanomedicine(s) under theMicroscope. Mol. Pharmaceutics 8, 2101–2141 (2011).
 3. Duncan, R. & Richardson, S. C. W. Endocytosis and Intracellular Traicking as Gateways for Nanomedicine Delivery: Opportunities 
and Challenges. Mol. Pharmaceutics 9, 2380–2402 (2012).
 4. Venditto, V. J. & Szoka, F. C. Jr. Cancer nanomedicines: So many papers and so few drugs! Adv. Drug Deli. Rev. 65, 80–88, https://doi.
org/10.1016/j.addr.2012.09.038 (2013).
 5. Palumbo, R. et al. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-
pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des. Devel. her. 9, 
2189–2199, https://doi.org/10.2147/DDDT.S79563 (2015).
 6. Rom, J. et al. Eicacy and toxicity proile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. 
Anticancer Drugs 25, 219–224, https://doi.org/10.1097/CAD.0000000000000037 (2014).
 7. Batist, G. et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and 
cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of 
metastatic breast cancer. J Clin. Oncol. 19, 1444–1454, https://doi.org/10.1200/JCO.2001.19.5.1444 (2001).
 8. Goldberg, M. S. et al. Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine 8, 299–308 (2013).
 9. Barenholz, Y. C. Doxil® — he irst FDA-approved nano-drug: Lessons learned. J. Control. Rel. 160, 117–134 (2012).
 10. Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic 
accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986).
 11. Shweiki, D., Itin, A., Sofer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated 
angiogenesis. Nature 359, 843–845 (1992).
Data availability section. All data created during this research are openly available from the University of 
Strathclyde-Pure, at https://doi.org/10.15129/3b637e0e-6b92-4041-bac9-0ed9bc057bfd.
www.nature.com/scientificreports/
1 0SCIENTIFIC REPORTS |  (2018) 8:12318 ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
 12. Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 
16, 4604–4613 (1996).
 13. Kelly, B. D. Cell Type-Specific Regulation of Angiogenic Growth Factor Gene Expression and Induction of Angiogenesis in 
Nonischemic Tissue by a Constitutively Active Form of Hypoxia-Inducible Factor 1. Circ. Res. 93, 1074–1081, https://doi.
org/10.1161/01.res.0000102937.50486.1b (2003).
 14. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. AJPA 156, 1363–1380, https://doi.
org/10.1016/S0002-9440(10)65006-7 (2000).
 15. Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its 
heterogeneity. Adv. Drug Deliv. Rev. 91, 3–6, https://doi.org/10.1016/j.addr.2015.01.002 (2015).
 16. Jain, R. K., Martin, J. D. & Stylianopoulos, T. he Role of Mechanical Forces in Tumor Growth and herapy. Annu. Rev. Biomed. Eng. 
16, 321–346, https://doi.org/10.1146/annurev-bioeng-071813-105259 (2014).
 17. Lee, H. et al. 64Cu-MM-302 Positron Emission Tomography Quantiies Variability of Enhanced Permeability and Retention of 
Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin. Cancer Res. 23, 4190–4202, https://
doi.org/10.1158/1078-0432.CCR-16-3193 (2017).
 18. Torosean, S. et al. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial 
pressure. Nanomedicine 9, 151–158, https://doi.org/10.1016/j.nano.2012.07.002 (2013).
 19. Bennewith, K. L. & Durand, R. E. Quantifying transient hypoxia in human tumor xenograts by low cytometry. Cancer Res. 64, 
6183–6189 (2004).
 20. Vaupel, P. & Mayer, A. Hypoxia in Tumors: Pathogenesis-Related Classification, Characterization of Hypoxia Subtypes, and 
Associated Biological and Clinical Implications. Oxygen Trans. Tissue 36, 19–24, https://doi.org/10.1007/978-1-4939-0620-8_3 
(2014).
 21. Sriraman, S. K., Aryasomayajula, B. & Torchilin, V. P. Barriers to drug delivery in solid tumors. Tissue Barriers 2, e29528, https://doi.
org/10.2217/nnm.11.93 (2014).
 22. Semenza, G. L. & Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin 
gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12, 5447–5454 (1992).
 23. Semenza, G. L. Deining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625–634 (2009).
 24. Kaelin, W. G. & Ratclife, P. J. Jr. Oxygen Sensing by Metazoans: he Central Role of the HIF Hydroxylase Pathway. Mol. Cell 30, 
393–402, https://doi.org/10.1016/j.molcel.2008.04.009 (2008).
 25. Wenger, R. H., Stiehl, D. P. & Camenisch, G. Integration of Oxygen Signaling at the Consensus HRE. Sci. STKE. 2005, re12–re12 
(2005).
 26. Bando, H., Toi, M., Kitada, K. & Koike, M. Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-
MB-231. Biomed. Pharmacother. 57, 333–340 (2003).
 27. Mole, D. R. et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression 
proiling of hypoxia-inducible transcripts. J. Biol. Chem. 284, 16767–16775, https://doi.org/10.1074/jbc.M901790200 (2009).
 28. Brizel, D. M. et al. Tumor oxygenation predicts for the likelihood of distant metastases in human sot tissue sarcoma. Cancer Res. 56, 
941–943 (1996).
 29. Sundfør, K., Lyng, H. & Rofstad, E. K. Oxygen Tension and Vascular Density in Adenocarcinoma and Squamous Cell Carcinoma of 
the Uterine Cervix. Acta Oncol. 37, 665–670 (2009).
 30. Rohwer, N. & Cramer, T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death 
pathways. Drug Resist. Updat. 14, 191–201, https://doi.org/10.1016/j.drup.2011.03.001 (2011).
 31. Mao, C., Livezey, M., Kim, J. E. & Shapiro, D. J. Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations 
Upregulate the Unfolded Protein Response and are Killed by BHPI. Sci. Rep. 1–10, https://doi.org/10.1038/srep34753 (2016).
 32. Frezza, C. et al. Metabolic Proiling of Hypoxic Cells Revealed a Catabolic Signature Required for Cell Survival. PLoS ONE 6, e24411, 
https://doi.org/10.1371/journal.pone.0024411 (2011).
 33. Eales, K. L., Hollinshead, K. E. R. & Tennant, D. A. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis 5, e190, https://
doi.org/10.1038/oncsis.2015.50 (2016).
 34. Sun, R. C. & Denko, N. C. Hypoxic Regulation of Glutamine Metabolism through HIF1 and SIAH2 Supports Lipid Synthesis that Is 
Necessary for Tumor Growth. Cell Metab. 19, 285–292, https://doi.org/10.1016/j.cmet.2013.11.022 (2016).
 35. Mosesson, Y., Mills, G. B. & Yarden, Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer 8, 835–850, https://doi.
org/10.1038/nrc2521 (2008).
 36. Wang, Y. et al. Regulation of endocytosis via the oxygen-sensing pathway. Nat. Med. 15, 319–324, https://doi.org/10.1038/nm.1922 
(2009).
 37. King, H. W., Michael, M. Z. & Gleadle, J. M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 12, 421, 
https://doi.org/10.1186/1471-2407-12-421 (2012).
 38. Brenton, J. D., Carey, L. A., Ahmed, A. A. & Caldas, C. Molecular Classiication and Molecular Forecasting ofBreast Cancer: Ready 
for Clinical Application? JCO 23, 7350–7360 (2005).
 39. Lal, S., McCart Reed, A. E., de Luca, X. M. & Simpson, P. T. Molecular signatures in breast cancer. Methods 131, 135–146 (2017).
 40. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537–549 (2003).
 41. Harney, A. S. et al. Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by 
TIE2hi Macrophage-Derived VEGFA. Cancer Discov. 5, 932–943, https://doi.org/10.1158/2159-8290.CD-15-0012 (2015).
 42. Matsumoto, Y. et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nano. 
11, 533–538, https://doi.org/10.1038/nnano.2015.342 (2016).
 43. Miller, M. A. et al. Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts. Sci. 
Transl. Med. 9, https://doi.org/10.1126/scitranslmed.aal0225 (2017).
 44. Michiels, C., Tellier, C. & Feron, O. Cycling hypoxia: A key feature of the tumor microenvironment. Biochim. Biophys. Acta. 1866, 
76–86, https://doi.org/10.1016/j.bbcan.2016.06.004 (2016).
 45. Akinc, A. & Battaglia, G. Exploiting Endocytosis for Nanomedicines. Cold Spring Harbor Perspectives in Biology 5, a016980–a016980, 
https://doi.org/10.1101/cshperspect.a016980 (2013).
 46. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518–524 (2005).
 47. Massagué, J. & Obenauf, A. C. Metastatic colonization by circulating tumour cells. Nature 529, 298–306 (2016).
 48. Abramson, V. G. & Mayer, I. A. Molecular Heterogeneity of Triple-Negative Breast Cancer. Curr. Breast Cancer Rep. 6, 154–158 
(2014).
 49. Kim, J.-W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A 
metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177–185 (2006).
 50. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively 
downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187–197 (2006).
 51. Semenza, G. L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123, 
3664–3671 (2013).
 52. Jain, S. et al. Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions. Radiother. Oncol. 110, 342–347 
(2014).
www.nature.com/scientificreports/
1 1SCIENTIFIC REPORTS |  (2018) 8:12318 ȁǣ ? ?Ǥ ? ? ? ?Ȁ ? ? ? ? ?Ǧ ? ? ?Ǧ ? ? ? ? ?Ǧ ?
 53. Neshatian, M., Chung, S., Yohan, D., Yang, C. & Chithrani, D. B. Determining the Size Dependence of Colloidal Gold Nanoparticle 
Uptake in a Tumor-likeInterface (Hypoxic). Colloids Inter. Sci. Comm. 1, 57–61, https://doi.org/10.1016/j.colcom.2014.07.004 
(2014).
 54. Vaupel, P., Höckel, M. & Mayer, A. Detection and Characterization of Tumor Hypoxia Using pO 2Histography. Antioxid. Redox 
Signal. 9, 1221–1236 (2007).
 55. Place, T. L., Domann, F. E. & Case, A. J. Limitations of oxygen delivery to cells in culture: An underappreciated problem in basic and 
translational research. Free Rad. Biol. Med. 113, 311–322, https://doi.org/10.1016/j.freeradbiomed.2017.10.003 (2017).
 56. Blais, J. D. et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol. Cell. Biol. 24, 7469–7482 (2004).
 57. Ameri, K. et al. Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling 
pathway. Oncogene 26, 284–289 (2007).
 58. Duncan, R. & Pratten, M. K. Membrane economics in endocytic systems. J. heor. Biology 66, 727–735 (1977).
 59. Seib, F. P., Jones, A. T. & Duncan, R. Comparison of the endocytic properties of linear and branched PEIs, and cationic PAMAM 
dendrimers in B16f10 melanoma cells. J. Control. Release 117, 291–300, https://doi.org/10.1016/j.jconrel.2006.10.020 (2007).
 60. Fiorentino, I. et al. Energy independent uptake and release of polystyrene nanoparticles in primary mammalian cell cultures. Exp. 
Cell Res. 330, 240–247, https://doi.org/10.1016/j.yexcr.2014.09.017 (2015).
 61. Franovic, A. et al. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its 
overexpression in human cancer. Proc. Natl. Acad. Sci. USA 104, 13092–13097 (2007).
 62. Wang, Y. et al. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation 
of caveolin-1. Proc. Natl. Acad. Sci. USA 109, 4892–4897, https://doi.org/10.1073/pnas.1112129109 (2012).
 63. Bourseau-Guilmain, E. et al. Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells. Nat. 
Commun. 7, 11371, https://doi.org/10.1038/ncomms11371 (2016).
 64. Christianson, H. C. et al. Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and 
cytotoxicity. Oncotarget 8, 66960–66974, https://doi.org/10.18632/oncotarget.16921 (2017).
 65. Nehof, H., Parayath, N. N. & Taurin, S. he Inluence of Drug Loading on Caveolin-1 Mediated Intracellular Internalization of 
Doxorubicin Nanomicelles in vitro. J. Nanomed. Nanotechnol. 5, 197, https://doi.org/10.4172/2157-7439.1000197 (2014).
 66. Kang, J. et al. Caveolin-1 Modulates Docetaxel-Induced Cell Death in Breast Cancer Cell Subtypes through Diferent Mechanisms. 
Cancer Res. Treat. 48, 715–726 (2016).
 67. Wang, T. et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and 
metastasis. Proc. Natl. Acad. Sci. USA 111, E3234–E3242 (2014).
 68. Cavadas, M. A. S. et al. REST mediates resolution of HIF-dependent gene expression in prolonged hypoxia. Sci. Rep. 5, 17851, 
https://doi.org/10.1038/srep17851 (2015).
 69. Wang, X. et al. Insulin Downregulates the Transcriptional Coregulator CITED2, an Inhibitor of Proangiogenic Function in 
Endothelial Cells. Diabetes 65, 3680–3690 (2016).
 70. Seo, K.-S. et al. SIRT2 regulates tumour hypoxia response by promoting HIF-1? hydroxylation. Oncogene 34, 1354–1362 (2014).
Acknowledgements
This research was supported by The Royal Society Research Grant RG140331 and Marie Curie FP7 Career 
Integration Grant 334134 within the 7th European Union Framework Program (F.P.S). W.J.B.’s PhD studentship 
is supported through the EPSRC Doctoral Training Partnership (EP/M508159/1), University of Strathclyde.
Author Contributions
W.J.B. designed and performed experiments; acquired, analysed and interpreted the data; generated and edited 
the manuscript. F.P.S. conceived the study, interpreted data and edited the manuscript. Both authors designed the 
research and discussed the results.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-30517-3.
Competing Interests: he authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional ailiations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. he images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© he Author(s) 2018
